{
  "api_version": "1",
  "request": {
    "url": "https://clinicaltrialsfind.com/api/v1/search.json?condition=Cirrhosis+of+the+Liver&page=2",
    "query": {
      "condition": "Cirrhosis of the Liver",
      "page": 2
    },
    "page_size": 10
  },
  "pagination": {
    "page": 2,
    "page_size": 10,
    "total_count": 10,
    "total_pages": 1,
    "next_page_url": null,
    "previous_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?condition=Cirrhosis+of+the+Liver&page=1&page_size=10"
  },
  "source": "remote",
  "last_synced_at": "2026-07-23T14:22:40.421Z",
  "attribution": "Data derived from public ClinicalTrials.gov records. The official record at https://clinicaltrials.gov/ remains the source of truth for current availability, contacts, and full study details.",
  "notes": [
    "This endpoint exposes only public summary fields — no participant contact emails, phone numbers, or scraped investigator contact details.",
    "For contact information and full protocol detail, follow each trial's `official_url` to the ClinicalTrials.gov record.",
    "This API is a navigational aid. It does not provide medical advice, eligibility determinations, or compensation guarantees."
  ],
  "trials": [
    {
      "nct_id": "NCT02072746",
      "title": "Zinc Supplementation in Alcoholic Cirrhosis",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "NA"
      ],
      "conditions": [
        "Alcoholic Cirrhosis"
      ],
      "interventions": [
        {
          "name": "Zinc",
          "type": "DIETARY_SUPPLEMENT"
        },
        {
          "name": "Placebo",
          "type": "DIETARY_SUPPLEMENT"
        }
      ],
      "intervention_types": [
        "DIETARY_SUPPLEMENT"
      ],
      "sponsor": "University of Louisville",
      "sponsor_class": "OTHER",
      "healthy_volunteers": true,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": "75 Years",
        "sex": "ALL",
        "summary": "18 Years to 75 Years"
      },
      "enrollment_count": 30,
      "start_date": "2010-02",
      "completion_date": "2019-03-01",
      "has_results": false,
      "last_update_posted_date": "2021-03-22",
      "last_synced_at": "2026-07-23T14:22:40.421Z",
      "location_count": 1,
      "location_summary": "Louisville, Kentucky",
      "locations": [
        {
          "city": "Louisville",
          "state": "Kentucky"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT02072746"
    },
    {
      "nct_id": "NCT02147470",
      "title": "Evaluation of Renal Blood Flow Using Contrast Enhanced Ultrasound for Differential Diagnosis of Acute Kidney Injury in Cirrhotic Patients: A Pilot Study",
      "overall_status": "UNKNOWN",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "NA"
      ],
      "conditions": [
        "Liver Cirrhosis and Acute Kidney Injury"
      ],
      "interventions": [
        {
          "name": "Definity ultrasound contrast agent",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "University of Virginia",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 25,
      "start_date": "2013-02",
      "completion_date": null,
      "has_results": false,
      "last_update_posted_date": "2014-05-26",
      "last_synced_at": "2026-07-23T14:22:40.421Z",
      "location_count": 1,
      "location_summary": "Charlottesville, Virginia",
      "locations": [
        {
          "city": "Charlottesville",
          "state": "Virginia"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT02147470"
    },
    {
      "nct_id": "NCT03439254",
      "title": "Study Evaluating the Efficacy and Safety of Obeticholic Acid in Subjects With Compensated Cirrhosis Due to Nonalcoholic Steatohepatitis",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE3"
      ],
      "conditions": [
        "Compensated Cirrhosis",
        "Nonalcoholic Steatohepatitis"
      ],
      "interventions": [
        {
          "name": "Obeticholic acid (10 mg)",
          "type": "DRUG"
        },
        {
          "name": "Obeticholic acid (10 mg to 25 mg)",
          "type": "DRUG"
        },
        {
          "name": "Placebo",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Intercept Pharmaceuticals",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 919,
      "start_date": "2017-08-30",
      "completion_date": "2022-09-08",
      "has_results": true,
      "last_update_posted_date": "2023-10-23",
      "last_synced_at": "2026-07-23T14:22:40.421Z",
      "location_count": 120,
      "location_summary": "Dothan, Alabama • Madison, Alabama • Chandler, Arizona + 96 more",
      "locations": [
        {
          "city": "Dothan",
          "state": "Alabama"
        },
        {
          "city": "Madison",
          "state": "Alabama"
        },
        {
          "city": "Chandler",
          "state": "Arizona"
        },
        {
          "city": "Glendale",
          "state": "Arizona"
        },
        {
          "city": "Tucson",
          "state": "Arizona"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT03439254"
    },
    {
      "nct_id": "NCT00368225",
      "title": "Transplant-Related Accelerated Progression of Hepatitis C",
      "overall_status": "COMPLETED",
      "study_type": "OBSERVATIONAL",
      "phases": [],
      "conditions": [
        "Hepatitis C",
        "Cirrhosis"
      ],
      "interventions": [],
      "intervention_types": [],
      "sponsor": "National Institutes of Health Clinical Center (CC)",
      "sponsor_class": "NIH",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 100,
      "start_date": "2006-06-22",
      "completion_date": "2009-01-22",
      "has_results": false,
      "last_update_posted_date": "2017-07-02",
      "last_synced_at": "2026-07-23T14:22:40.421Z",
      "location_count": 3,
      "location_summary": "Washington D.C., District of Columbia • Bethesda, Maryland • Falls Church, Virginia",
      "locations": [
        {
          "city": "Washington D.C.",
          "state": "District of Columbia"
        },
        {
          "city": "Bethesda",
          "state": "Maryland"
        },
        {
          "city": "Falls Church",
          "state": "Virginia"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT00368225"
    },
    {
      "nct_id": "NCT02984124",
      "title": "Communication During Hospitalization About Resuscitation Trial",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE2",
        "PHASE3"
      ],
      "conditions": [
        "Severe Life-limiting COPD",
        "Severe Life-limiting Heart Failure",
        "Severe Life-limiting Cirrhosis",
        "Severe Life-limiting Malignancy",
        "Severe Functional Impairment",
        "End Stage Renal Disease"
      ],
      "interventions": [
        {
          "name": "Informed Assent Discussion",
          "type": "BEHAVIORAL"
        },
        {
          "name": "Usual Care with Attention Control",
          "type": "BEHAVIORAL"
        }
      ],
      "intervention_types": [
        "BEHAVIORAL"
      ],
      "sponsor": "University of Vermont",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "65 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "65 Years and older"
      },
      "enrollment_count": 182,
      "start_date": "2016-12",
      "completion_date": "2025-12",
      "has_results": false,
      "last_update_posted_date": "2026-05-29",
      "last_synced_at": "2026-07-23T14:22:40.421Z",
      "location_count": 4,
      "location_summary": "Chapel Hill, North Carolina • Charleston, South Carolina • Burlington, Vermont + 1 more",
      "locations": [
        {
          "city": "Chapel Hill",
          "state": "North Carolina"
        },
        {
          "city": "Charleston",
          "state": "South Carolina"
        },
        {
          "city": "Burlington",
          "state": "Vermont"
        },
        {
          "city": "Seattle",
          "state": "Washington"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT02984124"
    },
    {
      "nct_id": "NCT02168361",
      "title": "The SIM-SOF Trial for Hepatitis C",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE4"
      ],
      "conditions": [
        "Chronic Hepatitis C"
      ],
      "interventions": [
        {
          "name": "Pegylated Interferon alfa-2b",
          "type": "DRUG"
        },
        {
          "name": "Simeprevir",
          "type": "DRUG"
        },
        {
          "name": "Ribavirin",
          "type": "DRUG"
        },
        {
          "name": "Sofosbuvir",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Center For Hepatitis C, Atlanta, GA",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 93,
      "start_date": "2013-12",
      "completion_date": "2015-04",
      "has_results": true,
      "last_update_posted_date": "2016-03-14",
      "last_synced_at": "2026-07-23T14:22:40.421Z",
      "location_count": 1,
      "location_summary": "Atlanta, Georgia",
      "locations": [
        {
          "city": "Atlanta",
          "state": "Georgia"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT02168361"
    },
    {
      "nct_id": "NCT05548452",
      "title": "Intestinal Microbiota Transplant in Alcohol-Associated Liver Disease",
      "overall_status": "RECRUITING",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1",
        "PHASE2"
      ],
      "conditions": [
        "Liver Disease; Alcohol-Related",
        "Cirrhosis",
        "Alcohol Use Disorder"
      ],
      "interventions": [
        {
          "name": "Intestinal Microbiota Transplant (IMT) Capsules",
          "type": "DRUG"
        },
        {
          "name": "Placebo Capsules",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Virginia Commonwealth University",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 80,
      "start_date": "2022-11-21",
      "completion_date": "2027-11",
      "has_results": false,
      "last_update_posted_date": "2026-07-14",
      "last_synced_at": "2026-07-23T14:22:40.421Z",
      "location_count": 2,
      "location_summary": "Richmond, Virginia",
      "locations": [
        {
          "city": "Richmond",
          "state": "Virginia"
        },
        {
          "city": "Richmond",
          "state": "Virginia"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT05548452"
    },
    {
      "nct_id": "NCT04497038",
      "title": "Cabozantinib in Patients With Advanced Hepatocellular Carcinoma With Child Pugh Class B Cirrhosis After First-Line Therapy",
      "overall_status": "TERMINATED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1",
        "PHASE2"
      ],
      "conditions": [
        "Advanced Adult Hepatocellular Carcinoma"
      ],
      "interventions": [
        {
          "name": "Cabozantinib",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "University of Michigan Rogel Cancer Center",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 3,
      "start_date": "2021-08-06",
      "completion_date": "2023-05-02",
      "has_results": true,
      "last_update_posted_date": "2024-08-06",
      "last_synced_at": "2026-07-23T14:22:40.421Z",
      "location_count": 4,
      "location_summary": "Chicago, Illinois • Ann Arbor, Michigan • Dallas, Texas",
      "locations": [
        {
          "city": "Chicago",
          "state": "Illinois"
        },
        {
          "city": "Chicago",
          "state": "Illinois"
        },
        {
          "city": "Ann Arbor",
          "state": "Michigan"
        },
        {
          "city": "Dallas",
          "state": "Texas"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT04497038"
    },
    {
      "nct_id": "NCT01672879",
      "title": "Simtuzumab (SIM, GS-6624) in the Treatment of Cirrhosis Due to NASH",
      "overall_status": "TERMINATED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE2"
      ],
      "conditions": [
        "Liver Fibrosis Due to NASH"
      ],
      "interventions": [
        {
          "name": "Placebo",
          "type": "BIOLOGICAL"
        },
        {
          "name": "SIM",
          "type": "BIOLOGICAL"
        }
      ],
      "intervention_types": [
        "BIOLOGICAL"
      ],
      "sponsor": "Gilead Sciences",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": "65 Years",
        "sex": "ALL",
        "summary": "18 Years to 65 Years"
      },
      "enrollment_count": 259,
      "start_date": "2012-10-29",
      "completion_date": "2017-01-03",
      "has_results": true,
      "last_update_posted_date": "2019-03-27",
      "last_synced_at": "2026-07-23T14:22:40.421Z",
      "location_count": 41,
      "location_summary": "Phoenix, Arizona • Coronado, California • San Diego, California + 35 more",
      "locations": [
        {
          "city": "Phoenix",
          "state": "Arizona"
        },
        {
          "city": "Coronado",
          "state": "California"
        },
        {
          "city": "San Diego",
          "state": "California"
        },
        {
          "city": "San Francisco",
          "state": "California"
        },
        {
          "city": "Aurora",
          "state": "Colorado"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT01672879"
    },
    {
      "nct_id": "NCT02939989",
      "title": "Efficacy and Safety of Glecaprevir (ABT-493)/Pibrentasvir (ABT 530) (GLE/PIB) in Combination With Sofosbuvir and Ribavirin in Participants With Hepatitis C Virus Who Did Not Respond to Treatment in a Previous AbbVie Clinical Study",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE3"
      ],
      "conditions": [
        "Hepatitis C Virus Infection"
      ],
      "interventions": [
        {
          "name": "Sofosbuvir",
          "type": "DRUG"
        },
        {
          "name": "Glecaprevir/Pibrentasvir",
          "type": "DRUG"
        },
        {
          "name": "Ribavirin",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "AbbVie",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "12 Years",
        "maximum_age": "99 Years",
        "sex": "ALL",
        "summary": "12 Years to 99 Years"
      },
      "enrollment_count": 33,
      "start_date": "2016-11-21",
      "completion_date": "2021-07-30",
      "has_results": true,
      "last_update_posted_date": "2022-05-04",
      "last_synced_at": "2026-07-23T14:22:40.421Z",
      "location_count": 8,
      "location_summary": "Dothan, Alabama • Los Angeles, California • Baltimore, Maryland + 5 more",
      "locations": [
        {
          "city": "Dothan",
          "state": "Alabama"
        },
        {
          "city": "Los Angeles",
          "state": "California"
        },
        {
          "city": "Baltimore",
          "state": "Maryland"
        },
        {
          "city": "Detroit",
          "state": "Michigan"
        },
        {
          "city": "Buffalo",
          "state": "New York"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT02939989"
    }
  ]
}